Show simple item record

dc.contributor.authorGil, Horacio
dc.contributor.authorMargaryan, Hasmik
dc.contributor.authorAzamat, Ismailov
dc.contributor.authorZiba, Bekturdieva
dc.contributor.authorBayram, Halmuratov
dc.contributor.authorNazirov, Pirimqul
dc.contributor.authorGomez, Diana
dc.contributor.authorSingh, Jatinder
dc.contributor.authorZayniddin, Sayfutdinov
dc.contributor.authorParpieva, Nargiza
dc.contributor.authorAchar, Jay
dc.date.accessioned2021-01-09T14:20:03Z
dc.date.available2021-01-09T14:20:03Z
dc.date.issued2021-01-06
dc.identifier.pmid33406316
dc.identifier.doi10.1111/tmi.13543
dc.identifier.urihttp://hdl.handle.net/10144/619815
dc.description.abstractObjectives In this retrospective study, we evaluated the diagnostic accuracy of molecular tests (MT) for the detection of DR‐TB, compared to the gold standard liquid‐based Drug Susceptibility Testing (DST) in Karakalpakstan. Methods A total of 6,670 specimens received in the Republican TB No 1 Hospital Laboratory of Karakalpakstan between January and July 2017 from new and retreatment patients were analyzed. Samples were tested using Xpert MTB/RIF and line probe assays (LPA) for the detection of mutations associated with resistance. The sensitivity and specificity of MTs were calculated relative to results based on DST. Results The accuracy of MT for detection of rifampicin resistance was high, with sensitivity and specificity over 98%. However, we observed reduced sensitivity of LPA for detection of resistance; 86% for isoniazid (95%CI 82‐90%), 86% for fluoroquinolones (95%CI 68‐96%), 70% for capreomycin (95%CI 46‐88%) and 23% for kanamycin (95%CI 13‐35%). Conclusions We show that MTs are a useful tool for rapid and safe diagnosis of DR‐TB, however, clinicians should be aware of their limitations. Although detection of rifampicin resistance was highly accurate, our data suggests that resistance mutations circulating in the Republic of Karakalpakstan for other drugs were not detected by the methods used here. This merits further investigation.en_US
dc.language.isoenen_US
dc.relation.urlhttps://doi.org/10.1111/tmi.13543en_US
dc.rightsThis article is protected by copyright. All rights reserved.en_US
dc.subjectDrug-resistant tuberculosis
dc.subjectGeneXpert
dc.subjectMycobacteria
dc.subjectdiagnostic accuracy
dc.subjectdrug susceptibility testing
dc.subjectline probe assay
dc.titleAccuracy of molecular drug susceptibility testing amongst tuberculosis patients in Karakalpakstan, Uzbekistan.en_US
dc.typeArticle
dc.identifier.eissn1365-3156
dc.contributor.departmentMedecins Sans Frontières (MSF), Nukus, Uzbekistan; Republican TB No 1 Hospital Laboratory of Karakalpakstan, Nukus, Uzbekistan; Republican TB No 1 Hospital of Karakalpakstan, Nukus, Uzbekistan; MSF, Amsterdam, Holland; MSF, Tashkent, Uzbekistan; Tuberculosis Institute, Tashkent, Uzbekistan; National Tuberculosis Reference Laboratory, Tashkent, Uzbekistan; MSF, London, UK9Karolinska Institutet, Stockholm, Swedenen_US
dc.identifier.journalTropical Medicine & International Healthen_US
dc.source.journaltitleTropical medicine & international health : TM & IH
refterms.dateFOA2021-01-09T14:20:04Z
dc.source.countryEngland


Files in this item

Thumbnail
Name:
tmi.13543.pdf
Size:
5.005Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record